Given that some prudent investors start to worry about the rising interest rates and look for debt-free companies, the early movers could check debt-free Cipher Pharmaceuticals (CPH), which has a lot of expertise in many dermatological products.
For instance, CPH produces excellent creams for acne (i.e. its well-known Epuris has 41% market share in Canada).
CPH is debt-free, profitable and dirt-cheap trading just 1.4 times its EBITDA.
And CPH has many growth drivers in 2021 because it has many promising drugs in the pipeline with very positive clinical trials to-date. Just my two cents.